Investing Profile

Diyong Xu

InvestorVC
Partner (previously Principal-VP-Associate-Analyst) at OrbiMed
orbimed.comNew York, New York
Photo of Diyong Xu, Partner at OrbiMed

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Stanford University Network
1415 CONNECTIONS
Dartmouth College Network
264 CONNECTIONS
Lazard Network
129 CONNECTIONS
Bender Helper Impact Network
80 CONNECTIONS
OrbiMed Network
39 CONNECTIONS
cb
OrbiMed Partner
$1M - $75.0M
$4.0M
5
$18B
CompanyStageDateRound SizeTotal Raised
Q32 Bio
Post Ipo EquityMay 2026$55M
Post Ipo EquityMar 2024$42M
Series BOct 2020$60M
Series AMay 2020$46M
$200M
Co-investors: David Grayzel (Atlas Venture), Isaac Manke (Acorn Bioventures)
OnCusp Therapeutics
Series AJan 2024$100M
$100M
Co-investors: Karen Hong (De Novo Ventures), Chong Xu (F-Prime Capital (formerly Fidelity Biosciences))
Private Equity Intern Bender Helper ImpactPresent
Private Equity Intern Flag Tree CapitalPresent
Investment Banking Intern Instream Partners LLCPresent
Investment Banking LazardPresent
Investment Banking Lazard Freres & Co.Present
Principal, Private Equity / Venture Capital OrbiMed AdvisorsPresent
Partner (previously Principal-VP-Associate-Analyst) OrbiMedPresent
Zhejiang University B.S. Biological Sciences
Dartmouth College M.S. Molecular and Cellular Biology
Stanford University M.S. Management Science and Engineering
Sign in with Google →
Sign in with Google →